Dr. Laszlo Radvanyi Laszlo was educated at the University of Toronto, earning a PhD in Clinical Biochemistry in 1996. He is currently the President & Scientific Director of the Ontario Institute for Cancer Research (OICR; https://oicr.on.ca/), bringing over 30 years of strong oncology research background in academia as well as leadership experience in international pharma and biotech. Laszlo joined OICR from EMD Serono (Merck KGaA), where he was Senior Vice President Global Head of the Immuno-Oncology (IO) Translational Innovation Platform (TIP) and Senior Scientific Advisor for Immunology and IO. While at EMD Serono, Laszlo rebuilt and re-organized the IO research platform and rejuvenated its target pipeline. Prior to joining EMD Serono, Laszlo was a Professor in the Department of Melanoma Medical Oncology at the University of Texas, MD Anderson Cancer Center in Houston for 10 years. While at MD Anderson, he ran an integrated clinical and basic research program in adoptive T-cell therapy for solid tumours and is an expert in the field of tumour-infiltrating lymphocyte (TIL) therapy. Laszlo was also the founding CSO for Iovance Therapeutics, commercializing TIL therapies for melanoma and other cancers and led research and development activities leading to two active Phase 2 INDs leading to regulatory approval. He also has 7 patents in the cancer immunotherapy and cell therapy field. Laszlo has been the recipient of numerous scientific awards and is a member of a number of scientific advisory boards, such as Keystone Conferences, and editorial boards, such as the Journal of Immunotherapy for Cancer (JITC). He also sits on a number of biotech advisory boards, such as Toronto Innovation Acceleration Partners (formerly MaRS Innovation) and other biotech companies and organizations.